A clinician's comments on the cyclophosphamide hematotoxicity biologically based risk assessment model.
Atkins
H L
HL
Ottawa Hospital Blood and Marrow Transplant Program, Ontario, Canada. harry.atkins@orcc.on.ca
D000208:Acute Disease; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000633:toxicity; D016465:Bone Marrow Purging; D003198:Computer Simulation; D003520:Cyclophosphamide / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006098:Granulocytes / Q000166:cytology / Q000187:drug effects; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000633:toxicity; D007951:Leukemia, Myeloid / Q000139:chemically induced; D008954:Models, Biological; D009190:Myelodysplastic Syndromes / Q000139:chemically induced; D016016:Proportional Hazards Models; D015203:Reproducibility of Results; D018570:Risk Assessment
D018906:Antineoplastic Agents, Alkylating; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide